# UBT251 Injection Phase II Clinical Study (CKD)

Study · id `cardio:ct-nct07134335` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07134335](<https://clinicaltrials.gov/study/NCT07134335>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07134335

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07134335. Randomized; double masking; primary purpose treatment. Start 2025-09-01 (actual); primary completion 2030-07-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07134335, source copy `cardio:ctgov-nct07134335-2026-11-03`, retrieved 2026-11-18)
- Started: 2025-09-01 (actual) (ClinicalTrials.gov record NCT07134335, source copy `cardio:ctgov-nct07134335-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2030-07-11 (anticipated) (ClinicalTrials.gov record NCT07134335, source copy `cardio:ctgov-nct07134335-2026-11-03`, retrieved 2026-11-18)
- Completion: 2030-07-11 (anticipated) (ClinicalTrials.gov record NCT07134335, source copy `cardio:ctgov-nct07134335-2026-11-03`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07134335, source copy `cardio:ctgov-nct07134335-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07134335-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: UBT251 Injection Phase II Clinical Study (CKD)
- Condition: Obesity &Amp; Overweight
- Condition: Chronic Kidney Disease
- Intervention (Drug): UBT251
- Intervention (Drug): UBT251
- Intervention (Drug): UBT251
- Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd. (`cardio:org-the-united-bio-technology-hengqin-co-ltd`)

## Provenance

Content hash: f5c5d590052414428e63d33f447f1d1659c7115bcac47695172024abd0b38f46
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
